Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study
Mario Messina(University of Siena), Chiara Stagnaro(University of Pisa), Rossella Angotti(University of Siena), Daniele Cammelli(Azienda Ospedaliero-Universitaria Careggi), R Marcolongo(University of Padua), Salvatore De Vita(University of Udine), Marta Mosca(University of Pisa), Elena Cavallaro(University of Udine), Florenzo Iannone(University of Bari Aldo Moro), Bruno Frediani(University of Siena), Giuseppe Lopalco(University of Bari Aldo Moro), Serena Colafrancesco(Sapienza University of Rome), Antonio Vitale(University of Siena), Ombretta Viapiana(University of Verona), Rosaria Talarico(University of Pisa), Paolo Sfriso(University of Padua), Elena Silvestri(University of Florence), G. De Marchi(University of Udine), Alessandra Soriano, Leonardo Punzi(University of Padua), Elena Verrecchia(Università Cattolica del Sacro Cuore), Giovanni Lapadula(University of Bari Aldo Moro), Francesco La Torre(Ospedale Vito Fazzi), Manuela Pardeo(Istituti di Ricovero e Cura a Carattere Scientifico), Rolando Cimaz(Meyer Children's Hospital), Maria Cristina Maggio(Hospital Universitario Santa Cristina), Stefano Gentileschi(University of Siena), Giacomo Emmi(Azienda Ospedaliero-Universitaria Careggi), Marco Cattalini(University of Brescia), Roberta Priori(Sapienza University of Rome), Gianfranco Vitiello(University of Florence), Antonella Insalaco(Bambino Gesù Children's Hospital), Fabrizio De Benedetti(Vita-Salute San Raffaele University), Anǵela Tincani(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Raffaele Manna(Università Cattolica del Sacro Cuore), Giuseppe Paolazzi(Ospedale Santa Chiara), Micol Frassi(University of Brescia), Jurgen Sota(University of Siena), Paola Galozzi(University of Padua), Guido Valesini(Sapienza University of Rome), Alma Nunzia Olivieri(University of Naples Federico II), Maria Alessio(University of Naples Federico II), Lucia Cerrito(Università Cattolica del Sacro Cuore), Claudia Fabiani(University of Siena), Francesca Ricci(University of Padua), Mauro Galeazzi(University of Siena), Carlo Salvarani(Azienda Sanitaria Unità Locale di Reggio Emilia), Romina Gallizzi(University of Messina), Armin Maier(Ospedale di Bolzano)
Cited by 82
Related Papers
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
|Journal of Thrombosis and Haemostasis|2006|7.1k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia
|JAMA Internal Medicine|2020|732
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726
Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
|Frontiers in Pharmacology|2019|616